CliffBio
small molecule

ERMEZA

LEVOTHYROXINE SODIUM

Loss of exclusivityFebruary 2035latest FDA-listed patent expiry
CompanyMylan →View the full company profile on CliffBio

Drug detail

Brand nameERMEZA
Active ingredientLEVOTHYROXINE SODIUM
Strength150MCG/5ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusRX

Listed patents

PatentExpiresType
9345772February 2035product

More from Mylan

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ERMEZA patent cliff — loss of exclusivity February 2035 | CliffBio